Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shailesh Gandhi

Pain Medicine Oak Lawn, IL Medical Doctor

NPI 1992758783 CMS profile 362545

4440 W 95Th St, Oak Lawn, IL 60453

Open in the dashboard

General payments

$16,966

344 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shailesh Gandhi of Oak Lawn, IL is reported in the CMS Open Payments database as having received $16,966 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,252 57
2024 General $1,640 52
2023 General $1,887 62
2022 General $2,861 44
2021 General $1,794 41
2020 General $1,186 34
2019 General $3,346 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shailesh Gandhi
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Shailesh Gandhi were reported at $4,252. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Shailesh Gandhi Pain Medicine median Middle half National median
2019 $3,346 $506 $144–$1,566 $163
2020 $1,186 $315 $96–$934 $114
2021 $1,794 $452 $134–$1,237 $132
2022 $2,861 $475 $124–$1,407 $149
2023 $1,887 $480 $136–$1,384 $160
2024 $1,640 $521 $164–$1,511 $164
2025 $4,252 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,738 58 payments
  2. Boston Scientific Corporation $2,680 51 payments
  3. Saluda Medical Americas, Inc. $2,144 6 payments
  4. SPR Therapeutics, Inc $1,449 53 payments
  5. Spinal Simplicity, LLC $1,188 14 payments
  6. Genesys Orthopedics Systems, L.L.C. $1,048 6 payments
  7. Nevro Corp. $1,034 24 payments
  8. Medtronic USA, Inc. $972 16 payments
  9. TerSera Therapeutics LLC $638 27 payments
  10. Collegium Pharmaceutical, Inc. $370 20 payments
  11. Other $2,705 69 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,353 324 payments
  2. Travel and Lodging $4,598 19 payments
  3. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. Evoke $2,053 5 payments
  2. SPRINT PNS System $1,449 53 payments
  3. HA MINUTEMAN G3-R $1,188 14 payments
  4. Sacroiliac Joint Fusion System $1,048 6 payments
  5. Proclaim Family of SCS IPGs $1,041 11 payments
  6. SYNCHROMED $822 11 payments
  7. PROCLAIM $795 25 payments
  8. Omnia $597 14 payments
  9. SUPERION $505 11 payments
  10. Prialt $471 19 payments
  11. Other $7,384 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

430

Median for Pain Management: 951

Drug cost

$7,175

Median for Pain Management: $26,034

Branded share of claims

46.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 136 $2,383
Lidocaine Generic 13 $1,035
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 46 $904
Gabapentin Generic 68 $881
Pregabalin Generic 35 $483
Morphine Sulfate Er Morphine Sulfate Brand 18 $456
Tramadol Hcl Generic 46 $368
Baclofen Generic 16 $193
Tizanidine Hcl Generic 15 $177
Naproxen Generic 26 $176

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$85,128

Medicare's payments for the services billed

Medicare patients

247

Average age 73

Services billed

946

149 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 30%
Depression 30%
Diabetes 28%
Chronic kidney disease 21%
Atrial fibrillation 18%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $122
$122 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $74
$74 — —
GABLOFEN
  • Piramal Critical Care $73
$73 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $41
$41 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record